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Objectives This study aimed to assess PD-1gene polymorphism in salivary gland tumors in patients referred to Khalili 
Hospital in Shiraz. 
Methods This case-control study evaluated 48 patients with salivary gland tumors and 100 age- and sex-matched 
healthy controls. First, 5cc blood samples were obtained from patients and transferred to vials containing anti-
coagulated EDTA. DNA was extracted, and polymerase chain reaction-restriction fragment length polymorphism (PCR-
RFLP) was performed on the samples. The PD-1 gene genotype was determined using the Fermentas kit. After 24 hours 
of incubation, all the samples were electrophoresed. The genotypes were reported based on the size of bands, and the 
chi-square test was applied. To compare the alleles, the Fisher’s Exact test was applied. The Yates correction was used 
to compare the genotype and genotypic alleles based on the tumor grade. 
Results The mean age was 44.81±15.69 years in patients and 46.54± 13.86 years in controls. Statistical analysis did not 
show any significant difference in PD1 gene polymorphism between the two groups (P=0.098). No significant correlation 
was found between the genotype frequency and lymph node involvement (P=0.06), tumor genotype (P=0.12), side 
(right or left) (P=0.22), tumor location (P=0.27), and size or invasion of the tumor to the surrounding tissue (P=0.14). 
PD1.3 genotype frequency did not differ significantly between malignant and benign tumors (P=0.6). 
Conclusion This study did not reveal any significant difference in genotype frequency of PD1.3 in the patient and control 
groups; however, further studies are needed with a larger sample size to obtain more accurate results. 




In mammals, the salivary glands are exocrine glands 
producing saliva through a system of ducts. Salivary gland 
tumors are uncommon, and often involve the parotid, 
submandibular, and sublingual glands.
1
 In the United States, 
less than 3% of all malignancies and less than 6% of the 
head and neck cancerous tumors are formed in the salivary 
glands.
2
 The global prevalence of salivary gland tumors is 
4.7% (4.0% to 5.4%) for benign tumors and 0.9% (0.5% to 
1.3%) for malignant tumors in 100,000 people, annually.
3-5
 
PD1, also called the CD279, is a protein that induces 
peripheral tolerance in T lymphocytes via negative 
regulation. It belongs to the immunoglobulin superfamily 
and CTLA4/CD28. This molecule induces a negative signal 
to the T cells during the reaction with its ligands, leading to 
regulation of the immune system and prevention of 
autoimmunity.
6
 Several studies have suggested a 
relationship between the polymorphism of this gene and the 
emergence of various autoimmune diseases as well as some 
cancers. Some studies have been conducted in Iran on 
salivary gland tumors. In one study conducted in Shiraz, the 
most common benign tumors were pleomorphic adenoma, 
Warthin’s tumor, myoepithelioma, basal cell adenoma, and 
oncocytoma in order of importance.
7, 8
 
There is much evidence that the immune system affects the 
function of the salivary glands. Cytokines play a significant 
role in the onset and continuation of inflammation in the 
secretory glands, and any imbalance between the pro-
inflammatory and anti-inflammatory cytokines can lead to 
further damage to the glands and adversely affect their 
secretion function.
9
 Furthermore, it has been shown that 
increased expression of TLR3 in salivary glands results in 
rapid loss of its activity. This phenomenon is associated 
with the production of type 1 interferon and other 
inflammatory cytokines in the salivary glands.
10
 Kobayashi 
(2005) studied the expression of PD-1/PD-L1 gene in the 
salivary glands of patients with Sjogren's syndrome and 
showed that PD-1 had been expressed by T lymphocytes 
and PD-L1 had been expressed by the epithelial cells of the 
salivary glands, which had not been expressed at the onset 
of Sjogren's syndrome.
11
 PD-1 has two ligands: PD-Ls on 
cell lines and tissues expressed in epithelial cancers such as 
pancreatic, lung, esophagus and cervical cancers as well as 
squamous cell carcinoma.
12-17
 A number of single 
nucleotide polymorphisms (SNPs) have been identified in 
the PD-1 gene, which may be associated with cancer 
potency or various autoimmune diseases. Some of these 
polymorphisms may affect the copy process and gene 
expression.
14-16
 Since the relationship between this gene and 
salivary gland tumors has not been determined, this study 
was conducted to assess PD-1gene polymorphism in 
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salivary gland tumors in patients referred to Khalili 
Hospital in Shiraz. 
 
Materials and Methods 
In this case-control study, 48 patients with salivary gland 
tumors (mucoepidermoid carcinoma, adenoid cystic 
carcinoma, squamous cell carcinoma, epithelial 
myoepithelial carcinoma, and salivary duct carcinoma), and 
100 healthy age- and sex-matched controls were evaluated 
who did not have any history of cancer or autoimmune 
diseases. Approval was obtained from the Ethics 
Committee of Shiraz University of Medical Sciences 
(IR.SUMS.DENTAl.REC N: 8695183). 
 
The sample size was calculated to be 48.  
 
n= 
                 
       
  
 = 48 
= 1.96      d=0.1,    = 1.28      power test=90% 
 
To increase the study precision, we doubled the sample size 
for the control group. The patients were selected by a 
physician after confirming their diagnosis based on clinical 
findings and the pathology reports. Patients who were 
reluctant to participate in the study and those who had a 
history of malignancy, autoimmune or genetic diseases and 
those whose first-degree relatives had the aforementioned 
conditions were excluded from the study. After obtaining 
informed consent, approximately 5 cc of blood was 
obtained from the patients and transferred into vials 
containing EDTA. Then, DNA was extracted using the 
DNA extraction kit, and polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP) was 
performed on the samples. Using the enzyme limiting 
Fermentas kit (USA) to determine the genotype of the PD-1 
gene and after 24 hours of incubation, the product was 
electrophoresed on agarose gel, and the genotypes were 
reported based on the size of the bands. 
DNA extraction: 
Using the salting out technique, DNA was extracted from 5 
mL of peripheral blood in both the patient and control 
groups. After determining the concentration of DNA using 
a Bio Photometer device, 300 ng concentration of DNA was 
prepared using the following formula:  
N1V1=N2V2 
Where N1 is the known DNA concentration, N2 is the 
required concentration, V1 is the required volume and V2 is 
the final volume. 
PCR: 
PCR-RFLP was used to determine the genotype of 
individuals at position +7146 G/A in PD-1 gene (PD-1.3). 
For this purpose, the DNA fragment was amplified with a 
length of 456 open pairs using specific primers amplified by 
PCR. The presence and size of the desired part were 
confirmed by running on 2% agarose gel. The amplified 
fragment was then subjected to the enzymatic fragmentation 
of the Pst I restriction enzyme and determined based on the 
pattern of the parts of the individuals’ genotype. In the 
duplicate piece, there were 2 fragmentation sites for the PstI 
enzyme, which were added to another cutting location in 
the mutation position in the presence of the A allele. 
Therefore, individuals with GG genotype after fracture with 
enzymes had fragments of 310, 127 and 19 open pairs, and 
individuals with GA genotype had fragments of 310, 212, 
127, 98, 19 open pairs. Individuals with AA genotype with 
127, 212 and 98 open pairs were also detected. The 19-pair 
piece was not detected, since it was short on the gel. In 
addition, the pieces of 98 and 127 open pairs were not 
distinguishable due to slight differences in the gel but were 
considered a single-band. The data were analyzed by the 
SPSS software version 18. To compare the frequency of 
genotypes and alleles between the two groups, the chi-
square test was applied. To compare the alleles, the Fisher’s 
Exact test was used. Furthermore, the Yates Correction was 
used to compare the genotype and genotypic alleles based 
on the tumor grade. The algorithms in Arlequin (version 
3.1) were used to determine whether the studied groups had 




Our study population included 48 patients with salivary 
gland tumors with a mean age of 44.81 ± 15.69 years. Of 
which, 23 (48%) were males with an average age of 47.47 ± 
16.39 years, and 25 (52%) were females with an average 
age of 42.46 ± 14.98 years. The control group consisted of 
100 healthy subjects with a mean age of 46.54 ± 13.86 
years (47%), 47 males with a mean age of 51.12 ± 11.48 
years and 53 females with a mean age of 42.41 ± 14.61 
years. Of the 48 patients, 16 (33%) had malignant tumors 
and 32 (67%) had benign tumors. The most common type 
of malignant tumors was mucoepidermoid carcinoma (n=9, 
56.3%), and the most common type of benign tumors was 
pleomorphic adenoma (n=28, 87.5%). The tumor stage was 
determined based on the TNM staging system, and it was 
determined that the tumors were mainly in stages II and III 
(31.3%) (Tables 1 and 2). Data analysis revealed that the 
most frequent genotype was GG in 43 (89.6%) and 73 
(73%) subjects in the patient and control groups, 
respectively. The lowest frequency was related to AA 
genotype with a frequency of zero in the patient group and 
1(1%) in the control group. We used the sub-group analysis 
for genotype analysis, since in both case and control group, 
the frequency of AA genotype was extremely low (Table 3). 
The results indicated that homozygote GG genotype was 
more frequent in both the patient and control groups, but it 
did not have a statistically significant difference in terms of 
SNP+7146G/A gene PD-1 between the two groups 
(P=0.098). The results demonstrated that the G allele, the 
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wild allele and no mutation, were the dominant allele in the 
case and the control groups, respectively and there was no 
significant difference between the case and control groups.  
Table 1- Clinical and Pathological Characteristics of 






Male 8 (50%) 






Adenoid cystic carcinoma 5 (31.3%) 






Parotid gland 13 (92.9%) 
Sublingual gland 1 (7.1%) 
Missing 2 
Tumor side 
Right 4 (33.3%) 
Left 8 (66.7%) 
Missing 4 
TNM stage 
I 1 (7.1%) 
II 5 (35.7%) 
III 5 (35.7%) 




1 4 (33.3%) 
2 6 (50%) 




Free 10 (71.4%) 




T1 1 (7.1%) 
T2 6 (42.9%) 
T3 7 (50%) 
Missing 2 
Metastasis 
No 14 (100%) 
Missing 2 
 
Table 2- Clinical and Pathological Characteristics of Benign 










Pleomorphic adenoma 28(87.5%) 
Warthins tumor 3(9.4%) 
Parotid gland 1(3.1%) 
Tumor 
location 
Parotid gland 12(92.3%) 













G allele had the highest frequency in both the patient and 
control groups, and A allele was the least frequent. 
Statistical analysis showed no significant difference 
between the frequency of G and other alleles in the PD-1.3 
position between the patient and control groups (P = 0.07, P 
= 0.09, respectively). Analysis of the data suggested a close 
but not significant relationship between genotypes PD-1.3 
position and lymph nodes involvement by the tumor. (P = 
0.06).  
Table 3- Frequency of Genotypes and Alleles in the Patient and 
Control Groups 

























































No significant correlation was found between the genotype 
frequency and lymph node involvement (P=0.06), tumor 
genotype (P=0.12), side (right or left) (P=0.22), tumor 
location (P=0.27), and size or invasion of the tumor to the 
surrounding tissues (P=0.14). Also, PD1.3 genotype 
frequency did not differ significantly between the malignant 
and benign tumors (P=0.6).  
The frequency of PD-1.3 alleles in the patient and control 
groups showed that there was no significant difference in 
PD-1.3 (+7146 G/A) position, and G and A alleles. The 
frequency of G allele was 93% and 86%, and the frequency 
of A allele was 7% and 14% in the patient and control 




The study results indicated that polymorphism of PD1.3 
gene was not significantly different in the patient and 
control groups. Furthermore, there was no significant 
relationship between the frequency of PD1.3 genotypes and 
lymph node involvement, tumor location, tumor position, 
tumor size, invasion to the surrounding tissues, and 
malignant and benign tumors. During the immune response, 
the T cells activated in the secondary lymphoid tissue are 
prepared to migrate to infected tissues. The binding of the 
TCR-CD3 complex to the MHC-complex is essential for 
the first stage of T cell activity. The second signal, known 
as the stimulant, is required to propagate cloning and 
various activities of the T cells’ specific antigen. The 
balance between the stimulatory and inhibitory sequences 
maintains the immunological balance and prevents the 
formation of autoimmunity.
18
 The PD-1 gene polymorphism 
is a determining factor in regulation of immune responses to 
various diseases, including autoimmune diseases. The 
response of the receptor to its peptides, PD-L1 and PD-L2, 
generates a preventive message for the activity of the cell.
18
 
Many studies have been conducted to investigate the 
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association between PD-1 gene polymorphism and 
autoimmune diseases and tumors. Mojtahedi et al. (2012) 
studied 200 patients with colon cancer and compared them 
to 200 healthy individuals at the Cancer Research Center of 
Shiraz. The polymorphism of PD-1.5 C/T gene was 
significantly observed at position 1/5.
19
 The present study 
did not report the same results, since the results did not 
show significant differences between the patient and control 
groups. In this regard, Haghshenas et al. (2011) conducted a 
study in Shiraz on 443 women with breast cancer and 
compared them to healthy controls in terms of PD-1.5 gene 
polymorphism. The results indicated that there was no 
significant relationship between the two groups.
20
 In 
addition, they did not find a significant relationship 
regarding the development of tumor, metastasis to the 
lymph nodes, or distant metastasis, which was consistent 
with our results. In this area, Ghaderi et al. (2011) 
conducted a study on PD-1 gene polymorphism and the 
incidence of thyroid cancer in 105 patients, whose results 
did not show a significant relationship, but it was 
significant concerning haplotype and allele type.
21
 
Dehghani et al, (2009) in Fars Province conducted a study 
on the polymorphism of PDCD1 with CTLA-4 and p53 in 
women with the gestational trophoblastic disease, whose 
results revealed a relationship between PDCD1, CTLA-4 
and p53 gene polymorphism in these cases.
22
 Lin et al. 
(2004) studied 98 patients with lupus and 84 patients with 
rheumatoid arthritis in terms of PD-1 gene polymorphism. 
There was a significant relationship between PD-1 
polymorphism and rheumatoid arthritis, but this relationship 
was not significant in lupus disease.
23
 The results of the 
study conducted by Lin et al. are in line with the results 
obtained in the current study.  Savabkar et al. (2013) 
studied the polymorphism of PD-1.5 C/T in 166 cases with 
metastatic stomach cancer in Tehran. Although they did not 
draw definite conclusions about the polymorphism of PD-
1.5 C/T gene and gastric cancer, disruptions in the gene 
with the developing and progressing the disease were not 
irrelevant due to occurrence of some alleles in cases with 
gastric cancer.
24
 Using immunohistochemical methods and 
PCR, Bolstad et al. (2003) studied mRNA of salivary 
glands in patients with Sjogren’s syndrome. The expression 
of mRNA for Fas and FasL and CTLA-4 PD-1 in cases was 
significantly higher than in healthy controls.
25
 In this study, 
we focused on PD-1 gene polymorphism and did not study 
other genes. Using flow cytometry, Kobayashi et al. (2005) 
showed the occurrence of PD-1 and PD-L1. In cases with 
Sjogren, the average fluorescence intensity was 
significantly higher than that in healthy subjects.
11
 We did 
not use this method in our study. Differences regarding the 
autoimmune and cancer incidence rates in different 
populations may be due to different mechanisms of these 
diseases, as well as the different races of the subjects. It 
may also be due to the number of SNPs or the involvement 
of several genetic, immunological, environmental and other 
factors in these diseases. Although there was no significant 
association between the frequency of PD1.3 genotypes with 
lymph node involvement based on the type of tumor, more 
studies on larger populations are needed to confirm or reject 
this finding. Due to the small sample size of this study, 
findings should be interpreted with caution. This was a 





This study did not reveal any significant difference in 
genotype frequency of PD1.3 in the patient and control 
groups; however, further studies are needed with a larger 
sample size to obtain more accurate results. 
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